Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Conditions

Diseases of the Nervous System

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

This is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.

Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Novartis Pharmaceuticals
Start Date
02/28/2022
End Date
04/05/2022

For more information about this study, contact:

Kristen Torres

203.737.7496
kristen.torres@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Huned Patwa, MD
Professor of Neurology; Chief, VA Neurology Service; Chief, Division of Neuromuscular Medicine; Co-Director, MDA Clinic

Sub-Investigators

David Matuskey, MD
Gustavo A. Angarita, MD
Mariam Aboian, MD/PhD
Ming-Kai Chen, MD, PhD
Nabeel Nabulsi, PhD
Richard Carson, PhD
Yiyun Huang, PhD

Last Updated
03/09/2022
Study HIC
#2000026495

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information